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Abstract: The unprecedented epidemic spread of chikungunya worldwide illustrates the critical 
need for potent vaccines and therapeutic interventions. The morbidity and mortality associated 
with this arboviral infection has become a major public health problem in many countries across 
different continents. Increasing public–private partnerships have opened new avenues in research 
and development of vaccines. This review mainly focuses on the recent advances in patented 
approaches for chikungunya vaccine development and the forthcoming challenges.
Keywords: chikungunya, epidemics, CHIKV vaccine candidates, clinical trials, humans
Introduction
Chikungunya is an emerging arthritogenic arboviral illness caused by chikungunya virus 
(CHIKV), a member of the genus Alphavirus in the Togaviridae family. CHIKV is an 
enveloped, positive-sense, single-stranded RNA with 11.8 kb long linear genome with 
two open reading frames encoding four nonstructural replicase proteins (nsP1, nsP2, 
nsP3, and nsP4) and five structural proteins (three glycosylated envelope glycoproteins 
E1, E2, and E3, nonglycosylated nucleocapsid and cleavage product 6 k). CHIKV was 
first isolated during an epidemic in Tanganyika in 1953. In fact, the name “chikungunya” 
pronounced as “CHI-kən-GUUN-yə” is derived from the Kimakonde language of the 
Makonde tribe, which means “the bent walker/stooped walking” describing the contorted 
posture of a patient suffering with severe joint pain and other arthritic symptoms caused by 
this disease.1,2 The virus has evolved into three distinct geographical lineages with distinct 
genotypes – East/Central/South African (ECSA), Asian, and West African.3 Explosive 
outbreaks during the last decade worldwide have prompted National Institute of Allergy and 
Infectious Diseases (NIAID) to add CHIKV in the category C priority pathogen biodefense 
list (https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens).
The virus transmission takes place by the arthropod vectors, female Aedes aegyptica 
or Aedes albopictus mosquitoes; aggressive daytime feeders that also transmit dengue, 
zika and yellow fever.2 The routine sylvatic or nonhuman cycle involves other primates 
like apes and lemurs but during epidemics, chikungunya transmission can be continued 
by interhuman spread.4 A. albopictus – the Asian tiger mosquito – is a more cold-
tolerant mosquito and adaptation of a single amino-acid genetic mutation in the E1 
glycoprotein of CHIKV strains resulted in the epidemiologic shift of chikungunya 
from tropical to temperate regions of the world.5
Search strategy
This review is based on all types of studies related to CHIKV vaccine develop-
ment in humans and discussed the various vaccine approaches in detail. The articles 
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were retrieved by PubMed, OVID, EMBASE, Google 
search, and clinical trials registries for relevant studies 
using search strategy (Search (((((((chickungunya) OR 
chikungunya) OR ((Chikungunya Fever) OR Chikungunya 
virus))) AND (((((((inactivated vaccine) OR live attenuated 
vaccine) OR virus like particle vaccine) OR recombinant vac-
cine) OR chikungunya virus vaccine)) OR ((((chikungunya 
virus vaccine) OR vaccine) OR conjugate vaccine) OR 
virus like protein))) AND ((((((((clinical trials) OR ran-
dom) OR randomly) OR phase 1) OR phase 2) OR phase 
3) OR randomised controlled trial) OR randomized))) NOT 
((animals) NOT humans)). The search included publications 
that are recent till August, 2018. We have searched for studies 
to be included irrespective of any language or publication 
status. We have also manually searched the references and 
bibliographies of all the included studies and related review 
articles for any additional studies. Figure 1 shows the 
flowchart for screening and study selection process.
epidemiology
The dissemination of the CHIKV is geographically dis-
tributed in tropical and subtropical regions of East Africa, 
Southeast Asia, and Western Pacific. The persistent increase 
in unchecked vector population, immunologically naïve 
population, climatic changes, urbanization, and ease of 
global travel has elevated the risk for geographical expansion 
of CHIKV to nonendemic regions. The first outbreak of 
chikungunya was documented in late 1950s to early 1960s 
in Bangkok and from 1963 to 1973 in India, affecting thou-
sands of people. The next two major outbreaks were reported 
in coastal regions of Kenya in 2004 and consequently 
spread to numerous islands of Indian Ocean over a period 
of next 4 years. The largest outbreak occurred in islands of 
La-Reunion, in the western part of Indian Ocean in 2005 in 
which 266,000 cases and 254 deaths were reported by French 
public health authorities.6 Several other countries includ-
ing Mauritius, Seychelles, Madagascar, Gabon, Comoros 
and Mayotte, India, Sri Lanka, Indonesia, Thailand, 
Senegal, Philippines, Laos, Guinea, Taiwan, Vietnam, 
Myanmar, Singapore, Malaysia, Cambodia, and Pakistan 
also reported chikungunya cases. Massive chikungunya 
outbreaks were documented in India during 2006–2007, 
affecting .1.5 million people.7,8 The disease then spread 
rapidly toward Pacific islands causing significant outbreaks 
in the Caribbean Islands in 2011.9 Post the upsurge of Indian 
Ocean outbreak, the disease spread to a few places in Europe 
also. The CHIKV was later introduced in Americas in late 
2013. The number of chikungunya cases spiraled during 
the devastating 2014–2015 epidemic in several North, 
Central, and South American countries resulting in millions 
of reported cases.10,11 This was one of the most prominently 
reported outbreaks of CHIKV in Americas. The series of 
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Strategy developments for Chikungunya vaccine in humans
chikungunya epidemics globally has shown dramatic increase 
in incidence rate of CHIKV over the last decade. The virus 
has been reported in more than 60 countries from various 
WHO regions with approximately one million cases and 
fatality rate of 0.1% per year globally.12–14
Clinical presentation
The pathologic mechanism of this virus leads to acute 
infection of several weeks, which can persist for months 
with incubation period of 2–12 days.15 CHIKV affects all age 
groups with dengue-like symptoms characterized by nausea, 
fever, chills/rigors, headache, polyarthralagia, myalgia, 
photophobia, and skin rash.8,16 The hallmark characteristics 
of CHIKV infection are saddle-back fever, polyarthralgia 
(mainly in small joints – ankles, toes, wrists, and phalanges), 
and a petechial or maculopapular rash (mainly on face, limbs, 
and trunk).17,18 Strikingly, recovery from an acute arthritic ill-
ness (high viral load ~108–109 viral copies/mL) takes few days 
to couple of weeks, though convalescence can be prolonged. 
In some chronic cases, the clinical manifestations may persist 
for several months or even years disquieting quality of life. 
The chronic symptoms mainly include recurrent low-grade 
body ache, fatigue, neuritis, and persistent swelling and 
incapacitating inflammation of the joints.19 The major factors 
for CHIKV persistence may include genetic susceptibility, 
reinfection, exaggerated proinflammatory response leading to 
tissue damage, evasion of host defense machinery, activation 
of cryptic virus molecules, and autoimmune reactivity with 
viral and host antigens. Serious complications are uncommon. 
However, in rare cases CHIKV can be fatal, primarily in the 
elderly (.65 years), pregnant women, neonates exposed 
intrapartum (vertical transmission), young children (espe-
cially under 1 year), and persons with preexisting medical 
conditions like hypertension, diabetes, and heart disorders. 
Children atypically suffer from severe manifestations of 
CHIKV disease with neurologic complications like seizures, 
impaired consciousness, blindness due to retro-bulbar neuri-
tis, and acute flaccid paralysis.20
immunologic basis of CHiKv vaccine 
development
CHIKV infection confers life-long immunity.21 The acti-
vation of innate immune system, in particular, Type I 
interferons, is fundamental to clearance of acute CHIKV 
infections. Besides, numerous other innate immune cells 
like macrophages, natural killer cells, and dendritic cells 
also play pivotal role as robust responders to early CHIKV 
infections. However, recently, the protective and pathologic 
attributes of the innate immunity have been implicated in 
the pathogenesis of CHIKV infections.22 The components of 
adaptive immunity – both humoral and cellular immunity – 
also imply a crucial role in the protection and elimination of 
CHIKV-induced infections. However, the humoral immune 
response (B cell response) plays decisive role in protection 
against CHIKV infection compared to cellular immunity in 
human and mouse models.23 There are neutralizing antibod-
ies produced through humoral immune mechanism against 
glycoproteins on the outer surfaces of CHIKV envelope 
that mediate the clearing of viremia.24 Generally, IgM is 
detectable between days 2 and 8 of illness and is normally 
present for only up to 3 months, while convalescent IgG is 
measurable from day 4 and persists for years. Recently, Chua 
et al described that anti-CHIKV IgM targets E1–E2 surface 
glycoproteins simultaneously rather than E1 or E2 individu-
ally, and thus helps in designing more sensitive and reliable 
IgM assay using an optimized native antigen.25 Additionally, 
CD8+ T cells in cell-mediated immunity play an important 
role in development of robust protective immunity in con-
trolling acute infections (early phase), whereas CD4+ T cells 
mediate immune response during chronic phase.26 However, 
there is an urgent need for future research to understand the 
mechanism of immunopathogenesis of adaptive immunity 
during the sequel of chronic CHIKV infection in humans 
and vaccine development.
Recent developments in CHiKv vaccines
The inadequate traditional mosquito control measures, dearth 
of herd immunity, rapid globalization, sporadic and episodic 
outbreaks worldwide, and high disease-associated morbidity 
emphasize the need for research and development of effective 
vaccines for this neglected tropical disease – “Chikungunya”. 
Vaccines are one of the most important medical contributions 
and cost-effective public health interventions of the 20th cen-
tury to prevent communicable diseases. Unlike dengue, the 
development of an ideal CHIKV vaccine is pragmatic owing 
to the low antigenic variability of the virus. Despite vigorous 
efforts and support by researchers, vaccine producers, policy 
makers, and funding agencies across the globe, no vaccine 
has been licensed to combat CHIKV infections hitherto. 
Advances in the field of vaccinology in 21st century have led 
to the development of .20 CHIKV vaccine candidates using 
diverse vaccine strategies. These include live-attenuated vac-
cines, whole-virus inactivated vaccines, recombinant virus-
vectored vaccines, inactivated virus-like particles (VLPs), 
DNA vaccines, mRNA-based vaccines, synthetic vaccines, 
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vaccine candidates exhibit wide array of advantages as well 
as disadvantages in manufacturing, dosage, safety, efficacy, 
scalable production, and cost effectiveness during preclinical 
and clinical phases of development. Recently, chikungunya 
has also been added in the revised list of WHO Research and 
Development Blueprint preparedness for priority diseases/
pathogens most likely to cause epidemics in the annual review 
meeting held at Geneva, Switzerland, in January 2017.30
In this review, the major breakthroughs in the develop-
ment of CHIKV vaccines that have entered human clinical 
trial testing have been discussed in detail. Figure 2 illustrates 
the various strategies projected for CHIKV vaccine develop-
ment in humans.
Live-attenuated CHiKv vaccines
The early attempts to develop CHIKV vaccine began in 1962 
with the isolation of a CHIKV strain 15,561 from a viremic 
patient in Thailand. The wild-type strain was serially pas-
saged by investigators in African green monkey kidney cells 
at the Walter Reed Army Institute of Research (WRAIR) and 
in human MRC-5 cells by the US Army Medical Research 
Institute of Infectious Diseases (USAMRIID) and attenu-
ated strain CHIK 181/Clone 25 was selected as the “vaccine 
seed”. Chikungunya vaccine was manufactured at The Salk 
Institute-Government Services Division (TSI-GSD) in 
1984 in collaboration with the US Department of Defense 
(DoD).31,32 The attenuated TSI-GSD-218 revealed promising 
results in Phase I and Phase II trials conducted at USAMRIID 
and the University of Maryland Center for Vaccine Develop-
ment, respectively.33,34 No significant difference in local and 
systemic reactogenicity parameters between alphavirus-naive 
volunteers (n=15) and placebo groups was observed in 
Phase I study. In Phase II randomized, double-blind trial, 
73 volunteers (age 18–40 years) were recruited, of which 
59 volunteers were immunized with single subcutaneous dose 
of vaccine and 14 placebos received MRC-5 tissue culture 
fluid. Forty out of 58 serologically evaluable volunteers 
(69%) were seroconverted within 14 days, 57 (98%) were 
seroconverted ($1:20 by PRNT50) by 28 days, and 85% at 
1 year. Five of 59 (8%) vaccinees developed transient mild 
arthralgia and none was reported by the placebo group (n=14). 
However, the number and severity of local and systemic 
reactions were similar in both the groups. Despite safe and 
highly immunogenic nature in clinical trials, TSI-GSD-218 
development was terminated long before origination of 
deadly outbreaks in 2005 due to lack of funds, uncertainty 
about safety of bulk production, ambiguity about its misuse 
as a biologic warfare threat, and limited market for vaccine 
supply. However, the resurgence of chikungunya in islands of 
Caribbean and Indian Ocean raised the urgent need of tech-
nology transfers of this potential US military CHIKV vaccine. 
Five companies across the globe signed the material transfer 
agreement, of which only one pharmaceutical company has 
successfully developed the vaccine, which shows promis-
ing results in preclinical studies, and is ready for Phase I 
clinical trial.32 Strikingly, a recent study by Gorchakov et al 
has raised the concern of safety issues on the use of attenu-
ated 181/clone 25 CHIV vaccine strain.35 Attenuation of 
strain 181/clone 25 is attained by only two individual point 
mutations in structural E2 gene and reversions to wild-type 
sequences may result in phenotypic instability, accounting 
for mild reactogenic symptoms (transient arthralgia in 8% of 
∆
Figure 2 various strategies projected for chikungunya vaccine development in humans.
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Strategy developments for Chikungunya vaccine in humans
alphavirus-naïve volunteers), thus emphasizing the need for 
improvement of 181/clone 25 CHIKV vaccine.
Another novel live-attenuated CHIK/internal ribosomal 
entry site (IRES) vaccine candidate derived from La Reunion 
outbreak strain has been developed based on engineering two 
IRES elements in the CHIKV genome in order to overcome 
reversion issues of previous vaccine. This vaccine has shown 
very promising safety and efficacy outcomes in multiple pre-
clinical models.36–39 Takeda has recently decided to project 
this potential CHIK/IRES vaccine candidate toward clinical 
evaluation.40 Over the past year, Zydus Cadila, an Indian 
health care company, collaborated with the Japanese, Takeda 
Pharmaceutical Company Limited for conducting joint 
research to accelerate the development of CHIKV vaccine. 
The joint venture has raised the hope of rapid advancement 
of CHIKV/IRES (v1/v2) to human trials in the near future.
Another attenuated vaccine strategy developed to limit 
reversions is the deletion in structural and nonstructural genes 
of La Reunion (LR-CHIKV) strain of ECSA genotype. Three 
different CHIKV vaccine candidates were developed; Δ5nsP3 
an attenuated virus with a large deletion of 180 nucleotides 
(60 amino acids) from the nsP3 replicase region; DREP-E DNA-
launched replicon vaccine with deletion of the region encoding 
the capsid protein; MVA-CE recombinant vaccinia Ankara virus 
expressing entire structural (C-E3-E2-6K-E1) protein. A recent 
study showed that the monovalent, single dose of attenuated 
Δ5 virus vaccine was the safest, most efficacious, durable, and 
generated protective antibody and T cellular responses with 
long-term memory in preclinical models.41,42 These promising 
results of attenuated Δ5nsP3 vaccine candidate named VLA1553 
have recently marked its entry into a Phase I trial sponsored by 
a European biotech company – Valneva, Austria GmbH.43
whole-virus-inactivated CHiKv vaccines
The early work on the production of inactivated CHIKV 
vaccine began in 1967. The whole virus “seed culture” of 
CHIKV strain 15,561 grown in frozen African green monkey 
kidney tissue culture cells was inactivated using formalin, fol-
lowed by purification.44 Harrison et al administered formalin-
inactivated vaccine in two doses given twice (either 0.5 mL 
or 1 mL) in 16 healthy volunteers (aged 21–55 years) divided 
equally into 2 groups (n=8).45 The results showed 100% sero-
conversion rate (plaque reduction neutralization test [PRNT], 
complement fixation and hemagglutination assays) in both 
the groups without eliciting any local and systemic reactions. 
Despite excellent immunogenic response, the development 
of formalin-killed CHIKV vaccine was halted due to high 
manufacturing costs involving high biocontainment facilities. 
The major drawback was difficulty in comparison of results 
with other vaccine studies due to difference in dosage of 
vaccine inoculum used.
After more than three decades, another novel purified, 
noninfectious, inactivated CHIKV vaccine candidate has been 
developed using ECSA clinical virus isolates (CHK/03/06) 
obtained during 2006 outbreak in India and propagated 
in Vero and MRC-5 cells. The chemical inactivation of 
stabilized virus formulation was done using formalin or 
beta-propiolactone.8,46 Bharat Biotech International Limited 
filed several patents (US 8865184, EP 2720715 B1, WO 
2017123932 A1) related to inactivated CHIKV vaccine 
formulation. Subsequently, after successful production and 
preclinical animal testing, the approved vaccine has advanced 
for Phase I clinical trial (CTRI/2017/02/007755).47
vLP CHiKv vaccines
In contrast to traditional attenuated and inactivated vaccine 
approaches, use of VLP has proven to be a new highly 
efficacious vaccine approach as these are nonreplicating, 
noninfectious, and self-assembled multiprotein viral 
constructs resembling native alphavirus. The novel strategy 
involves transfection of embryonic kidney (HEK-293) cells 
with optimized codons encoding structural protein genes 
from West African CHIKV strain 37997, resulting in the 
production of VLPs with selective expression of E1 and E2 
glycoproteins in cell culture supernatant. In preclinical animal 
model, immunization with these VLPs induces high-titer 
neutralizing antibodies against enveloped glycoproteins that 
provide protection against viremia after high-dose challenge 
with wild-type virus.48,49 The novel VLPs vaccine platform 
became the first recombinant vaccine prototype to enter the 
Phase I clinical trial (NCT01489358) in 2011. VRC 311 was a 
nonrandomized, open-label trial in 25 adult volunteers (aged 
18–50 years) enrolled at the National Institutes of Health, 
USA. Participants receive three intramuscular injections of 
VLP vaccine (VRC-CHKVLP059-00-VP) without adjuvant 
in three dosage groups 10, 20, or 40 µg at weeks 0, 4, and 
20.50 Overall, vaccine was well tolerated, safe, and highly 
immunogenic with no serious adverse events (arthralgia). 
Remarkably, neutralizing antibodies were immunogenic 
after first and second vaccination in all participants with a 
significant boost observed 4 weeks after the third vaccination. 
However, the result of neutralization titers of this study 
cannot be extrapolated with previous clinical studies as these 
were measured by high-throughput flow cytometry-based 
assay as compared to the traditional PRNT assay. Based on 
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Phase-IIa randomized multicenter trial involving six cities 
in endemic regions of the Caribbean (NCT02562482).51 The 
study is sponsored by the National Institutes of Health and 
designed to recruit 400 healthy volunteers (aged 18–60 years) 
to evaluate the safety and immunogenicity of 20 mcg dose 
in a two-injection regimen at days 0 and 28. The primary 
endpoint results are anticipated to get published soon. Over 
the past year, PaxVax, a “US based vaccine manufacturing 
company,” has been working to develop a commercial 
manufacturing process of this potential CHIKV vaccine in 
alliance with the National Institute of Health and the DoD, 
USA. PaxVax has in-licensed the chikungunya VLP vaccine 
platform (PXVX0317) that has entered Phase IIb randomized 
clinical trial in 415 healthy adults to mitigate the high cost and 
associated risks (NCT03483961).52 Hence, the encouraging 
results from preclinical and Phase I trial represents VLPs 
as nonadjuvanated, safe, and highly immunogenic vaccine 
delivery platform capable of inducing humoral immune 
response. However, the demerit of this approach is that VLPs 
require multiple dosages to induce maximal immunogenicity, 
thereby increasing the cost of manufacturing and limiting the 
use in resource-constrained countries. Another drawback is 
their low-yield production. To overcome this issue, Metz 
and Pijlman in 2016 produced CHIKV-enveloped VLPs 
in insect cells using recombinant baculovirus expression 
platform, generating high yields on large scale with high 




Another modern vaccine approach uses attenuated measles 
virus (MV) Schwarz strain (MV/Schw), an RNA virus con-
taining a large 3.7 kb insert of structural coding gene (C-E3-
E2-6KE1) derived from La Reunion ECSA CHIKV strain. 
This recombinant MV-CHIKV vaccine generates VLPs under 
culture conditions. During preclinical testing, MV-CHIKV 
induces 100% seroprotection in mice with strong neutralizing 
and cellular immune response after second dose.54 This novel 
vaccine is developed by Themis Bioscience GmbH based on 
company’s proprietary Themaxyn® platform in collaboration 
with the Institut Pasteur. Based on the promising preclinical 
data (in mice and unpublished work in nonhuman primates), 
a Phase I, randomized clinical trial in 42 healthy volunteers 
(18–45 years) was done to assess the safety, tolerability, 
and immunogenicity of the recombinant vaccine (EudraCT 
no 2013-001084-23).55 The vaccine was given in three dose 
groups – low, medium, and high in two immunization 
schedules. In all dose groups, the candidate vaccine generated 
adequate neutralizing antibodies after first vaccination and 
100% seroconversion rate following the booster vaccination. 
The mild-to-moderate adverse events were noticed in all 
vaccinees; however, no vaccination-related serious adverse 
events were observed. After the successful Phase I trial, 
MV-CHIKV is being tested in three Phase II trials conducted 
simultaneously at three different locations (Europe, USA, and 
Caribbean island). Recently, the development of MV-CHIKV 
vaccine is being funded by Innovate UK (a nondepartmental 
public body, sponsored by the UK Department for Business, 
Innovation & Skills) for rapid clinical evaluation at large 
scale. Themis Bioscience has started a Phase II trial in 2016 
to determine the optimum dose of MV-CHIKV vaccine in 
320 participants (18–55 years) (NCT02861586).56 The study 
results are anticipated in 2018. Another Phase II trial has also 
been prompted by Themis Bioscience in collaboration with 
WRAIR, USA in a previously endemic area in Caribbean 
island (NCT03101111).57 A third Phase II trial of MV-CHIKV 
vaccine has been actively initiated by NIAID (NCT03028441) 
in three different states of USA (Georgia, Iowa, and Texas).58 
Overall, MV-CHIKV vaccine will be tested in more than 
600 healthy volunteers. Recently, another Phase II block-
randomized, prospective trial has commenced to compare 
the different formulations and dosages of MV-CHIKV vac-
cine in 60 healthy volunteers (NCT).59 These active ongoing 
trials will facilitate the novel MV-CHIKV vaccine candidate 
toward Phase III trials. The major advantage of this vaccine 
is its cost-effectiveness in manufacturing on large scale and 
requires comparably low effective doses in two-dose immu-
nization schedule. However, interference of the preexisting 
immunity against MV infection or vaccination must be taken 
into account in upcoming trials.
A novel CHIKV vaccine using advanced recombinant 
adenoviral technology, known as chimpanzee adenovirus 
Oxford 1 and 2 (ChAdOx1 and ChAdOx2), expressing 
structural proteins of CHIKV has been designed by Jenner 
Institute. Chimpanzee adenoviruses are nonenveloped, 
genetically stable, complex replication-deficient vectors, 
thermostable for storage at 45°C for 6 months, or ambient 
temperatures for much longer, and relevant among all age 
groups. The single dose of this vaccine has elicited safe and 
robust immune response against the encoded antigens in 
preclinical models and successfully advanced to good manu-
facturing practice production.60 The research group headed by 
Prof Arturo Reyes-Sandoval at Jenner Institute, University 
of Oxford financially supported by Innovate UK has recently 
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Strategy developments for Chikungunya vaccine in humans
clinical trial to evaluate its safety and immunogenicity.61,62 
This vaccine platform has been recognized by the WHO R&D 
Blueprint process for acceleration of large-scale production 
of CHIKV vaccine in response to outbreak preparedness.
mRNA-based CHiKv vaccines
Moderna Therapeutics – a US-based Biotech Company 
(originally named ModeRNA), develops drugs and vaccines 
based on mRNA technology. The innovative idea behind this 
promising drug approach is to deliver engineered mRNAs 
that direct cells to produce and express viral antigenic pro-
teins, emulating a viral infection that could elicit the immune 
response to generate antibodies. This multidisciplinary 
mRNA platform overcomes an array of challenges – evasion 
of immune system against engineered mRNAs, ample 
synthesis of desired protein inside target cells, and so on. 
An array of potent vaccines has been developed against 
emerging infectious diseases like influenza, chikungunya, 
ebola, and zika using this approach. Single dose of CHIKV 
mRNA vaccine encoding structural polyprotein of CHIKV 
provoked 100% protection in mice and strong antibody 
responses in nonhuman primates. Based on these promising 
results, CHIKV vaccine mRNA-1388 has advanced for 
Phase I study in humans (NCT03325075).63
Passive immunization
The passive immunization by transfer of purified polyclonal 
immunoglobulins from human sera has been widely 
demonstrated in many viral infections. Couderc et al 
used human immunoglobulins purified from convalescent 
phase plasma samples of CHIKV-infected patients in two 
susceptible mouse models.64 These immunoglobulins show 
high neutralizing activity in vitro, prevent viral dissemina-
tion in tissues, and show prophylactic and therapeutic effi-
cacy from lethal CHIKV infections. However, over the 
past years, a number of studies have also established that 
monoclonal antibodies also show protective efficacy in 
CHIKV-infected mice.65–68 These studies suggested that 
CHIKV immunoglobulins may act as antiviral therapy for 
high-risk human population exposed to CHIKV.69 Keeping 
these studies in view, anti-CHIKV hyperimmune intravenous 
immunoglobulins therapy undergoes an open, nonrandom-
ized Phase I/II trial (CHIKIVIG-01) in high-risk neonates 
born to CHIKV-viremic mothers (NCT02230163).70
vaccine trials in clinical pipeline
Work over the past 5 years has brought revolution in the 
CHIKV vaccine development; predominantly 2017/2018 
has marked the crucial year of this decade in which eleven 
promising clinical trials have been instigated in different 
phases of clinical pipeline worldwide. Table 1 summa-
rizes the various chikungunya vaccine strategies in human 
clinical trials.
Ongoing Phase i clinical trials
1. A novel CHIKV live-attenuated vaccine VLA1553 
(Δ5nsP3) has been projected for Phase I, randomized, 
multicenter trial in 120 healthy volunteers of age 
18–45 years to be enrolled across three locations in USA 
(ClinicalTrials.gov NCT03382964). Single immuniza-
tion of three dose levels – low (n=30), medium (n=30), 
and high (n=60) will be given intramuscularly to assess 
the safety and immunogenicity. This study has been 
sponsored by Valneva Austria GmbH.43
2. Another Phase I, randomized, open-label, placebo-
controlled, multicentric clinical trial has started recruiting 
healthy adults (n=60) of age 18–50 years to evaluate the 
safety, tolerability, and immunogenicity of inactivated 
CHIKV vaccine BBV87 in prime-boost regimen. This 
trial has been registered by Bharat Biotech International 
Ltd, Hyderabad with Clinical Trial Registry India 
(CTRI/2017/02/007755) in early 2017.47
3. A Phase I/II, double blinded, placebo-controlled, dose 
comparison trial (ClinicalTrials.gov NCT03028441) 
has started recruiting healthy adults aged 18–45 years 
(n=180) to evaluate the safety, immunogenicity, and 
schedule of live-attenuated, measles-vectored CHIKV 
vaccine (MV-CHIKV) developed by Themis Bioscience 
GmbH. The different dosage and immunization schedules 
will be evaluated. Themis’ prophylactic vaccine can-
didate (MV-CHIKV) is being tested and sponsored by 
NIAID, USA.58
4. The Jenner Institute, University of Oxford has designed 
a novel chimpanzee adenoviral vector-based vaccine, 
ChAdOx1- and ChAdOx2-expressing chikungunya 
structural antigens (capsid and envelope glycoprotein). 
After the preclinical validation of the single-dose, 
adjuvant-free CHIKV vaccine, this novel candidate vac-
cine has now entered into a Phase I clinical trial funded by 
UK’s Innovate agency.61 An open-label, nonrandomized, 
dose-escalation trial has started recruiting healthy vol-
unteers (age 18–50 years) to assess the safety and immu-
nogenicity of ChAdOx1 CHIK vaccine (CHIK001) 
(ClinicalTrials.gov NCT03590392).62
5. In late 2017, a Phase I, randomized, placebo-controlled, 
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Table 1 Chikungunya vaccine strategies in human clinical trial testing
Type of vaccine Manufacturer Phase of  
clinical trial




TSi-GSD-218 USAMRiiD/Salk institute for 
Biological Studies
Phase i NA Completed 
with results
33
Phase ii NA Completed 
with results
34




United States USAMRiiD and 
wRAiR, USA





Bharat Biotech international, 
Ltd, india













NiAiD Phase iia ClinicalTrials.gov NCT02562482 Active, not 
recruiting
51




Mv-CHiKv Themis Bioscience GmbH/
institut Pasteur in Paris, in 
collaboration with University 
of vienna, Austria 
Phase i eudraCT 2013-001084-23 Completed 
with results
55
Mv-CHiK-202 Themis Bioscience GmbH, in 
collaboration with University 
of vienna, Austria
Phase ii edura CT 2015-004037-26 Completed 56
ClinicalTrials.gov NCT02861586 Results awaited
Mv-CHiK-204 Themis Bioscience GmbH in 
collaboration with wRAiR, 
USA
Phase ii ClinicalTrials.gov NCT03101111 Active, not 
recruiting
57
Mv-CHiKv Themis Bioscience GmbH in 
collaboration with NiAiD
Phase i/ii ClinicalTrials.gov NCT03028441 Active, not 
recruiting
58
Mv-CHiKv Themis Bioscience in 
collaboration with Celerion 
Belfast





University of Oxford UK 
Research and innovation




mRNA vAL-181388 Moderna Therapeutics, 
USA and Defense Advanced 
Research Projects Agency






Universitaire de, Pointe-à- 
Pitre, Caribbean 
Phase i/ii ClinicalTrials.gov NCT02230163 Unknown 70
Abbreviations: Mv, measles virus; NA, not applicable; NiAiD, National institute of Allergy and infectious Diseases; USAMRiiD, United States Army Medical Research 
institute of infectious Diseases; TSi-GSD, The Salk institute-Government Services Division; vLP, virus-like particle; wRAiR, walter Reed Army institute of Research.
NCT03325075) to evaluate the safety and immuno-
genicity of CHIKV vaccine candidate dubbed mRNA 
VAL-181388 in healthy adults (n=60) in a nonendemic 
chikungunya region has been registered. The study 
involves three dosages in two immunization schedules. 
This study is sponsored by Moderna therapeutics sup-
ported by Defense Advanced Research Projects Agency, 
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Strategy developments for Chikungunya vaccine in humans
6. An open, nonrandomized Phase I/II trial (ClinicalTrials.
gov NCT02230163) has been initiated in 2014, with 
an aim to evaluate the safety and clinical evaluation of 
anti-CHIKV hyperimmune intravenous immunoglobu-
lins (CHIKIVIG-01) therapy to high-risk neonates born 
to CHIKV-viremic mothers. Unfortunately, very few 
neonates have been recruited till date and study has not 
been verified since last 2 years.70
7. Another commercial organization, Indian Immunologi-
cals Ltd, Hyderabad has received chikungunya vaccine 
seed materials (TSI-GSD-218 or 181/clone 25) from the 
USAMRIID. After the completion of initial preclinical 
toxicity studies and reinitiating the inactivated CHIKV 
vaccine development, the Phase I clinical trial is in 
progress.71
Ongoing Phase ii clinical trials
1. After the promising results of Phase I trial of VLP vaccine 
that consists of the E1, E2, and capsid proteins published 
by Chang et al,50 a Phase II, multicenter, randomized, 
placebo-controlled, double-blind trial of CHIKV VLP 
vaccine has been registered by NIAID (ClinicalTrials.gov 
NCT02562482) in 400 healthy adults (age 18–60 years) 
in CHIKV endemic areas. The primary objectives are to 
evaluate safety and tolerability of a two-injection vaccine 
regimen of VRC-CHKVLP059-00-VP at 20 mcg com-
pared to placebo (PBS) in healthy adults.51
2. Pax Vax has recently announced a Phase II parallel-
group, randomized, double-blind trial (ClinicalTrials.gov 
NCT03483961) to evaluate the safety and immunogenicity 
of VLP vaccine, PXVX0317 CHIKV-VLP, to different 
doses/formulations and schedules in 415 healthy adults 
(age 18–45 years) at three locations in USA. This trial 
has received the designation of priority access “Fast 
Track Program” from Food and Drug Administra-
tion of USA.52
3. Data from the Phase I trial of MV-based CHIKV vaccine 
trial are greatly anticipated. Recently, a Phase II, 
double-blinded, block-randomized, and placebo-controlled 
trial has been registered (ClinicalTrials.gov NCT02861586) 
to evaluate the optimal dose of measles-virus vaccine 
(MV-CHIK-202) by assessing immunogenicity, safety, and 
tolerability in 320 healthy volunteers (age 18–55 years). 
Two dose levels (low and high) at three immunization 
schedules will be assessed. This trial is being sponsored 
by Themis Bioscience GmBH in collaboration with 
University of Vienna, Austria. Very recently, the ongo-
ing trial has completed the recruitment of the participants 
and 263 healthy adults have been enrolled. The results 
are expected to be published soon.56
4. Another Phase II, comparator-controlled, random-
ized, double-blinded clinical trial (ClinicalTrials.gov 
NCT03101111) has started recruiting (n=100) healthy 
volunteers aged 21–50 years in a previously epidemic 
area (Puerto Rico) to evaluate the safety of live-attenuated 
MV-vectored CHIKV vaccine (MV-CHIK204). This 
trial is also sponsored by Themis Bioscience GmBH in 
collaboration with WRAIR.57
5. Themis Bioscience has initiated an additional Phase II 
randomized trial to investigate the safety, tolerability, and 
long-term durability of licensed MV-CHIKV in different 
formulations (lyophilized, liquid frozen, and liquid SPS) 
and dose regimens.59
Challenges in CHiKv vaccine development
The attempts to develop CHIKV vaccine began in the early 
1950s. The development of a safe and effective vaccine has 
been plagued by several challenges and quandaries. Unlike 
global dengue vaccine development for which more than 
60 clinical trials have been registered so far, only few CHIKV 
vaccine development initiatives have been completed, with 
limited vaccine candidates in preclinical and clinical pipeline 
using different technologic approaches. The challenges in 
developing a CHIKV vaccine can be categorized into three 
broad groups: clinical/therapeutic, social/demographic, 
and economic.
The major issue in the CHIKV vaccine field is the selection 
of biologic assays used to evaluate vaccine immunogenicity. 
The standard protection assay, that is, PRNT, is usually based 
on the measurement of neutralizing antibodies at baseline and 
post-vaccination. The interlab and interassay cutoff variation 
(two to threefold) in seroconversion rates and antibody titers 
exhibit significant shortcoming in vaccine trials. The low 
and waning immunogenicity of candidate vaccines in vac-
cinees and healthy controls is also a matter of great concern. 
The candidate vaccines in pipeline mainly focus on adult 
population, so their efficacy in pediatric population remains 
uncertain. The appropriate dosing requirement of varied 
CHIKV vaccine formulations, that is, multiple doses or single 
dose is better to maintain immunity against CHIKV, is also 
vacillating. Also, the substantial gap in our understanding of 
innate and adaptive immune responses that confer protection 
or pathologic immune response following a CHIKV infection 
poses another major challenge in vaccine development. The 
codistribution and coinfection of chikungunya and dengue 
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Despite the substantial increase in global travel to many 
CHIKV-endemic areas, the unpredictable epidemiology 
of chikungunya (sporadic outbreaks interspersed by long 
periods of quiescence) makes it less attractive for travel 
and tourism industry unlike diseases like yellow fever. 
The prevalence of chikungunya among the developing and 
underdeveloped countries with low literary levels, low per 
capita income, low living standards, and poor sanitation 
reduces the probability of marketing and commercialization 
of CHIKV vaccine in developed nations. Finally, a successful 
CHIKV vaccine candidate to enter the Phase III clinical tri-
als and licensure is challenging due to selection of a suitable 
location with adequate incidence of chikungunya in target 
population to demonstrate clinical efficacy. The huge capital 
investment, uncertain profits, and redundant regulatory path-
ways further reduce the interest of pharmaceutical companies 
and investors in CHIKV vaccine development. However, 
to overcome the financial risks and regulatory challenges, 
there is an urgent need for the global partnerships including 
national and international public, private, and government 
funding agencies, industry, researchers, clinicians, public 
health officials, and other global health stakeholders with 
an aim to develop new vaccines.
Summary
This review gives an insight about several CHIKV vac-
cines in clinical pipeline and puts into perspective the find-
ings, merits, and limitations of all clinical trials currently 
available. Although no vaccine is licensed at present, an 
effective vaccine for chikungunya will not only deter the ris-
ing trend of this infection but also contribute in limiting the 
disease-associated morbidity and health care costs involved 
in its management. In general, the ideal CHIKV vaccine to 
be licensed and ready for commercial use should be well 
tolerated, safe, adjuvant-free, and cost-effective, devoid of 
major vaccine-related adverse events such as arthralgia, have 
robust efficacy, and provide long-lasting immunity after a 
single dose in the general population. The efficacy of these 
vaccines in an endemic setting with limited resources would 
be greatly valuable as a significant burden of chikungunya 
lies in such regions.
This study will be helpful in suggesting which type of 
vaccine is clinically relevant and could be adopted for future 
clinical trials for estimation of safety, immunogenicity, 
tolerability, and efficacy. The rapid ongoing progress has 
raised hope for large-scale Phase III efficacy trials in endemic 
settings to begin soon. Although there is still a long way to go 
before a prophylactic vaccine for chikungunya is available, 
the vigorous restorative advancement during the last year 
makes the likelihood of having an effective vaccine in the 
near future high.
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